Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN
| Autor: | H, Fontaine, S, Kahi, C, Chazallon, M, Bourgine, A, Varaut, C, Buffet, O, Godon, J F, Meritet, Y, Saïdi, M L, Michel, D, Scott-Algara, J P, Aboulker, S, Pol, A, Vallet-Pichard |
|---|---|
| Přispěvatelé: | Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPC), Essais Thérapeutiques et Maladies Infectieuses, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pathogenèse des Virus de l'Hépatite B (PVHB), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service de Virologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Régulation des Infections Rétrovirales, Institut Pasteur [Paris], The trial was sponsored and funded by The National Agency for Research on Aids and Viral Hepatitis., Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pasteur [Paris] (IP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) |
| Rok vydání: | 2014 |
| Předmět: |
Male
MESH: Treatment Failure Gastroenterology law.invention 0302 clinical medicine Randomized controlled trial Recurrence law Vaccines DNA Prospective Studies Treatment Failure Prospective cohort study Anti hbv 0303 health sciences MESH: Middle Aged virus diseases Middle Aged Hepatitis B 3. Good health Female 030211 gastroenterology & hepatology MESH: Antiviral Agents Adult medicine.medical_specialty MESH: Hepatitis B Chronic Antiviral Agents DNA vaccination 03 medical and health sciences Hepatitis B Chronic Immune system Internal medicine medicine Humans Hepatitis B Vaccines 030304 developmental biology MESH: Hepatitis B Vaccines MESH: Humans business.industry MESH: Adult medicine.disease MESH: Prospective Studies MESH: Male MESH: Recurrence MESH: Vaccines DNA Discontinuation Clinical trial Immunology [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology business MESH: Female |
| Zdroj: | Gut Gut, BMJ Publishing Group, 2015, 64 (1), pp.139-147. ⟨10.1136/gutjnl-2013-305707⟩ Gut, 2015, 64 (1), pp.139-147. ⟨10.1136/gutjnl-2013-305707⟩ |
| ISSN: | 1468-3288 0017-5749 |
| DOI: | 10.1136/gutjnl-2013-305707 |
| Popis: | International audience; Objective: The antiviral efficacy of nucleos(t)ide analogues whose main limitation is relapse after discontinuation requires long-term therapy. To overcome the risk of relapse and virological breakthrough during long-term therapy, we performed a phase I/II, open, prospective, multicentre trial using a HBV envelope-expressing DNA vaccine.Design: 70 patients treated effectively with nucleos(t)ide analogues for a median of 3 years (HBV DNA 120 IU/mL) or impossibility of stopping treatment at week 48.Results: Reactivation occurred in 97% of each group after a median 28 days without liver failure but with an HBV DNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|